

Orthocell technologies and data to be presented at key orthopaedic conferences

- Positive data for Ortho-ACI™ cartilage regeneration treatment will be presented today at the Australian Orthopaedic Association and the Singapore Orthopaedic Association scientific meetings held in Brisbane and Singapore
- Orthocell's previously announced Tendon Bioreactor study (tendon outside the body) will also be presented today at the Australian Orthopaedic Association meeting

Perth, Australia; 15 October 2015: Regenerative medicine company Orthocell Limited is pleased to announce that positive, mean two year follow up data for its Ortho-ACI™ treatment for articular cartilage defects of the knee and ankle will be presented at two leading regional orthopaedic association annual scientific meetings today.

The retrospective analysis of 38 patients with symptomatic cartilage defects of the knee, showed 89% good to excellent outcomes on MRI assessment and 83% good to excellent outcomes on arthroscopic assessment. The study was conducted by leading Melbourne orthopaedic surgeon Dr Raymond Crowe at Epworth Hospital in conjunction with the University of WA (UWA).

The first of the presentations will be at the Australian Orthopaedic Association's (AOA) annual scientific meeting being held in Brisbane. This meeting brings together orthopaedic surgeons from Australia and the region and combines scientific and clinical presentations and discussions.

The data is also being presented at the Singaporean Orthopaedic Association's annual scientific meeting starting today.

"The presentation of this clinical data and research data at these important regional orthopaedic meetings demonstrates the effectiveness of Ortho-ACI™ in the regeneration of articular cartilage defects," said Orthocell CEO Mr Paul Anderson. "These defects are often difficult to treat and can lead to degenerative osteoarthritis so a consistent and cost effective treatment is highly desired.

"As the population ages, mobility becomes a significant issue and so doctors and patients are seeking out proven treatments to increase patients' mobility and quality of life," he said.

Further to this Orthocell's previously announced "tendon outside the body" Tendon Bioreactor work is also being presented at the AOA meeting by UWA Winthrop Professor M. H. Zheng.

This laboratory grown tendon innovation provides significant support for the mechanism of action for the Ortho-ATI™ tendon regeneration therapy being commercialised by Orthocell, and provides a potential pipeline product for full tendon replacement in the future.

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au

Investor relations

Rebecca Wilson
Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au

Media enquiries

Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.